@misc{oai:repo.qst.go.jp:00062491,
 author = {Tsuji, Hiroshi and Kato, Hiroyuki and Yanagi, Takeshi and Kamada, Tadashi and Tsujii, Hirohiko and 辻 比呂志 and 加藤 弘之 and 柳 剛 and 鎌田 正 and 辻井 博彦},
 month = {Mar},
 note = {Purpose: To evaluate the applicability of carbon ion beams in the treatment of choroidal melanoma, with regard to normal tissue morbidity and local tumor control. 
Methods and Materials: Between January 2001 and August 2007, 78 patients with a locally advanced or of unfavorable site choroidal melanoma were enrolled to a phase I/II clinical trial of carbon-ion radiotherapy (C-ion RT) at the National Institute of Radiological Sciences (NIRS). Primary endpoint of this study was normal tissue morbidity and secondary endpoints were local tumor control and patient survival. Of those, 72 patients were followed up more than 6 months and analyzed. 
Results: Twenty-six patients (36%) have developed neovascular glaucoma and 3 of them received enucleation because of eye pain due to elevated intraocular pressure. Incidence of neovascular glaucoma was dependent on the tumor size and site. Eight patients died until the date of analysis, 6 died of distant metastasis of melanoma and 2 died of intercurrent diseases. One patient developed local recurrence of the treated tumor and two developed intraocular recurrence outside the irradiated area, the other 69 tumors were still controlled locally on the date of analysis. Seventeen patients developed distant metastasis, 12 in the liver, 4 in the lung, and 1 in the bone. 5 year overall survival, cause-specific survival, and intraocular control rates were 79.7%, 83.1%, and 91.4%, respectively. 
Conclusion: C-ion RT can be applied to choroidal melanoma with an acceptable morbidity and sufficient anti-tumor effect, even in the tumors of unfavorable size or site., NIRS-MD Anderson Symposium on Clinical Issues for Particle Therapy},
 title = {Carbon Ion Radiotherapy for Eye Tumor},
 year = {2008}
}